Clinical Trial Update: Glucocorticoid Treatment in Transaortic Valve Replacement to Reduce the Incidence of Conduction Disturbances (GLUCO-TAVR). [Phase 4]

View source ↗

Summary

Phase 4 clinical trial examining glucocorticoid treatment in transcatheter aortic valve replacement (TAVR) to reduce conduction disturbances and conduction bloc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aortic Stenosis
• Heart Block

Drugs mentioned

• Glucocorticoid (glucocorticoid)

Snippet

Sponsor: Hospital General Universitario de Alicante | Conditions: Heart Block, Aortic Stenosis | Phase 4 | Status: UNKNOWN